STADA and Alvotech Launch Uzpruvo, First Stelara Biosimilar in Europe
Portfolio Pulse from Benzinga Newsdesk
STADA and Alvotech have launched Uzpruvo, the first approved biosimilar to Stelara in Europe, across major European markets. This launch follows the expiry of exclusivity rights linked to the European reference molecule patent, providing expanded access to a critical medicine in gastroenterology, dermatology, and rheumatology.
July 22, 2024 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alvotech, in partnership with STADA, has launched Uzpruvo, the first Stelara biosimilar in Europe. This launch is expected to expand market access and potentially increase revenues.
The launch of Uzpruvo as the first Stelara biosimilar in Europe positions Alvotech to capture market share in major European markets. This could lead to increased revenues and market presence.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80